灵芝-黄芪双向固态发酵菌质在制备降尿酸产品中的应用
The preparation method of Ganoderma lucidum-Astragalus bidirectional solid-state fermentation mycelium has solved the problem of low utilization of Ganoderma lucidum and Astragalus components in traditional processes, realizing bidirectional conversion and functional synergy of Ganoderma lucidum and Astragalus components, and preparing a highly efficient uric acid-lowering product with significant pharmacological effects and quality stability.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANDONG UNIV
- Filing Date
- 2026-05-14
- Publication Date
- 2026-07-17
AI Technical Summary
The existing traditional decoction or alcohol extraction processes for Ganoderma lucidum and Astragalus membranaceus cannot fully release fat-soluble components such as Ganoderma lucidum triterpenes. The bioavailability of isoflavones in Astragalus membranaceus is low. Furthermore, the existing solid-state fermentation technology has failed to achieve bidirectional conversion and functional synergy of components between Ganoderma lucidum and Astragalus membranaceus, making it difficult to meet the quality consistency requirements of uric acid-lowering products.
The preparation method of Ganoderma lucidum-Astragalus bidirectional solid-state fermentation mycelium involves inoculating Ganoderma lucidum mycelium into a composite substrate of rice and Astragalus, fermenting in the dark, and using Astragalus to induce secondary metabolism in Ganoderma lucidum to promote the conversion of flavonoid glycosides, phenolic acids and triterpenoids in Ganoderma lucidum. Combined with ultrasonic extraction technology of ethanol, a highly efficient uric acid-lowering product is prepared.
The product significantly increases the content of flavonoid glycosides, phenolic acids, and Ganoderma triterpenoids. It can reduce serum uric acid, improve liver and kidney damage caused by hyperuricemia, regulate intestinal flora structure and bile acid metabolism, and achieve product quality stability and synergistic pharmacological effects.
Smart Images
Figure CN122398882A_ABST